What does $62B buy you these days? A lot, says Take­da ex­ecs as the phar­ma play­er promis­es a block­buster R&D fu­ture

First comes the $62 bil­lion buy­out. Then comes the as­set auc­tion and re­or­ga­ni­za­tion to pay down debt. Now comes the de­tailed pledge of a big­ger, brighter fu­ture in drug de­vel­op­ment.

That’s where Take­da finds it­self on R&D day to­day, about 11 months af­ter clos­ing on their Shire ac­qui­si­tion. R&D chief Andy Plump is join­ing CEO Christophe We­ber and oth­er top mem­bers of the team to out­line a new set of pri­or­i­ties in the great­ly ex­pand­ed pipeline at Take­da, which has jumped in­to the top ranks of the world’s phar­ma gi­ants in the wake of the Shire deal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER